|
9.10.2020 |
EN |
Official Journal of the European Union |
C 335/9 |
Prior notification of a concentration
(Case M.9967 — Kohlberg/Mubadala/Partners Group/Pioneer UK Midco 1)
Candidate case for simplified procedure
(Text with EEA relevance)
(2020/C 335/08)
1.
On 1 October 2020, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Kohlberg & Co L.L.C. (U.S.A.), |
|
— |
Mubadala Investment Company PJSC (U.A.E.), |
|
— |
Partners Group AG (Switzerland), |
|
— |
Pioneer UK Midco 1 Limited (U.K.). |
Kolhberg & Co L.L.C., Mubadala Investment Company PJSC, and Partners Group AG will acquire within the meaning of Article 3(1)(b) and Article 3(4) of the Merger Regulation joint control of the whole of Pioneer UK Midco 1 Limited and its subsidiary PCI Pharma Services. The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are:|
— |
Kohlberg & Co., L.L.C.: a U.S. private equity management company specialised in investments in middle market companies, with a portfolio of companies active in various industries, such as industrial manufacturing, consumer products, business services, healthcare services and financial services. |
|
— |
Mubadala Investment Company PJSC: an Emirati public joint stock company focused on investment and development across a number of industries, including aerospace, ICT, semiconductors, metals and mining, renewable energy, oil and gas, petrochemicals, utilities, healthcare, real estate, pharma and medtech, agribusiness and it has a global portfolio of financial holdings. |
|
— |
Partners Group AG: a Swiss private markets investment management company operating globally in the areas of private equity, private real estate, private infrastructure and private debt. |
|
— |
Pioneer UK Midco 1 Limited: a U.K. holding company which owns and controls the group of companies doing business as PCI, the latter being a global provider of services to the pharmaceutical and biotech industries in clinical trial services, commercial packaging and development and manufacturing of pharmaceuticals. |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
4.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2), it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.
5.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.9967 — Kohlberg/Mubadala/Partners Group/Pioneer UK Midco 1
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).